
---
title: '独立于胰岛素调节血糖水平的新途径'
categories: 
 - 新媒体
 - 科学网
 - 博客
headimg: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202201/05/212958l2x8wyxxpa76qmx6.jpg'
author: 科学网
comments: false
date: Wed, 05 Jan 2022 21:33:00 GMT
thumbnail: 'https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202201/05/212958l2x8wyxxpa76qmx6.jpg'
---

<div>   
<p style="line-height: 2em;"><span style="font-family: "times new roman"; font-size: 24px;">独立于胰岛素调节血糖水平的新途径</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">——新分子通路控制血糖，规避胰岛素抵抗</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">诸平</span> </span></p><p><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202201/05/212958l2x8wyxxpa76qmx6.jpg" title alt="01 xu yu.jpg" referrerpolicy="no-referrer"><br></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Fig. 1 <a href="https://www.salk.edu/news-release/salk-researchers-find-a-new-route-for-regulating-blood-sugar-levels-independent-of-insulin/" target="_blank">Insulin and FGF1 both regulate blood sugar levels using independent pathways. Credit: Salk Institute</a></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202201/05/213048hck7280k8trlrkl2.jpg" title alt="02 xu yu.jpg" referrerpolicy="no-referrer"></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"> </span><span style="font-family: "times new roman"; font-size: 18px;">Fig. 2 </span><a href="https://www.salk.edu/news-release/salk-researchers-find-a-new-route-for-regulating-blood-sugar-levels-independent-of-insulin/" target="_blank" style="font-family: "times new roman"; font-size: 18px;">From left: Emma Tilley, Kyeongkyu Kim, Ruth Yu, Gencer Sancar, Ronald Evans, Annette Atkins and Michael Downes Credit: Salk Institute</a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">据索尔克研究所（</span><a href="https://www.salk.edu/news-release/salk-researchers-find-a-new-route-for-regulating-blood-sugar-levels-independent-of-insulin/" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Salk Institute</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>1<span style="font-size: 18px; font-family: 宋体;">月</span>4<span style="font-size: 18px; font-family: 宋体;">日报道，</span>100<span style="font-size: 18px; font-family: 宋体;">年前胰岛素的发现为数百万糖尿病患者打开了一扇通向生命和希望的大门。从那时起，在胰腺中产生的胰岛素就被认为是治疗以高血糖（葡萄糖）为特征的疾病（例如糖尿病）的主要手段。现在，索尔克研究所的科学家们发现了脂肪组织中产生的第二种分子，它与胰岛素一样，也能有效快速地调节血糖（</span></span><a href="https://www.sciencedaily.com/releases/2022/01/220104112231.htm" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">New route for regulating blood sugar levels independent of insulin</span></a><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">）。他们的发现可能会导致治疗糖尿病的新疗法的开发，也为代谢研究有希望的新途径奠定了基础。相关研究结果于</span>2022<span style="font-size: 18px; font-family: 宋体;">年</span>1<span style="font-size: 18px; font-family: 宋体;">月</span>4<span style="font-size: 18px; font-family: 宋体;">日已经在《细胞代谢》（</span>Cell Metabolism<span style="font-size: 18px; font-family: 宋体;">）杂志网站发表——</span>Gencer Sancar, Sihao Liu, Emanuel Gasser, Jacqueline G. Alvarez, Christopher Moutos, Kyeongkyu Kim, Tim van Zutphen, Yuhao Wang, Timothy F. Huddy, Brittany Ross, Yang Dai, David Zepeda, Brett Collins, Emma Tilley, Matthew J. Kolar, Ruth T. Yu, Annette R. Atkins, Theo H. van Dijk, Alan Saghatelian, Johan W. Jonker, Michael Downes, Ronald M. Evans. FGF1 and insulin control lipolysis by convergent pathways. Cell Metabolism, 2022; 34 (1): 171-183.e6.  DOI: </span><a href="http://dx.doi.org/10.1016/j.cmet.2021.12.004" target="_blank" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: "times new roman";">10.1016/j.cmet.2021.12.004</span></a><span style="font-size: 18px; font-family: "times new roman";">.</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">此研究表明，一种名为</span>FGF1<span style="font-size: 18px; font-family: 宋体;">的激素通过抑制脂肪分解即脂解（</span>lipolysis<span style="font-size: 18px; font-family: 宋体;">）来调节血糖。与胰岛素一样，</span>FGF1<span style="font-size: 18px; font-family: 宋体;">通过抑制脂肪分解来控制血糖，但这两种激素的作用方式不同。重要的是，这种差异可以使</span>FGF1<span style="font-size: 18px; font-family: 宋体;">能够安全、成功地降低患有胰岛素抵抗的人的血糖。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">共同通讯作者、分子和发育生物学教授罗纳德·埃文斯（</span>Ronald Evans<span style="font-size: 18px; font-family: 宋体;">）说：</span>“<span style="font-size: 18px; font-family: 宋体;">找到抑制脂肪分解和降低葡萄糖的第二种激素是一项科学突破。我们已经确定了一种调节脂肪分解的新参与者，它将帮助我们了解体内能量储存是如何管理的。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">当我们进食时，富含能量的脂肪和葡萄糖会进入血液。胰岛素通常将这些营养物质运送到肌肉和脂肪组织中的细胞，在那里它们可以立即使用或储存以备后用。在有胰岛素抵抗的人中，葡萄糖不能有效地从血液中去除，较高的脂解会增加脂肪酸水平。这些额外的脂肪酸会加速肝脏葡萄糖的产生，使已经很高的葡萄糖水平更加复杂。此外，脂肪酸在器官中积累，加剧了胰岛素抵抗</span>——<span style="font-size: 18px; font-family: 宋体;">糖尿病和肥胖症的特征。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">此前，该实验室的研究表明，注射</span>FGF1<span style="font-size: 18px; font-family: 宋体;">可显着降低小鼠的血糖，而慢性</span>FGF1<span style="font-size: 18px; font-family: 宋体;">治疗可缓解胰岛素抵抗。但它是如何工作的仍然是个谜。在目前的工作中，该团队调查了这些现象背后的机制以及它们之间的联系。首先，他们表明</span>FGF1<span style="font-size: 18px; font-family: 宋体;">抑制脂肪分解，就像胰岛素一样。然后他们发现</span>FGF1<span style="font-size: 18px; font-family: 宋体;">调节肝脏中葡萄糖的产生，就像胰岛素一样。这些相似之处使该小组想知道</span> FGF1<span style="font-size: 18px; font-family: 宋体;">和胰岛素是否使用相同的信号（通讯）途径来调节血糖。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">众所周知，胰岛素通过</span>PDE3B<span style="font-size: 18px; font-family: 宋体;">（一种启动信号通路的酶）抑制脂肪分解，因此该团队测试了一系列类似的酶，其中</span>PDE3B<span style="font-size: 18px; font-family: 宋体;">位居榜首。他们惊讶地发现</span>FGF1<span style="font-size: 18px; font-family: 宋体;">使用不同的途径</span>——PDE4<span style="font-size: 18px; font-family: 宋体;">。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">“<span style="font-size: 18px; font-family: 宋体;">这种机制基本上是第二个循环，具有平行途径的所有优点。在胰岛素抵抗中，胰岛素信号受损。但是，使用不同的信号级联，如果一个不起作用，另一个可以。那样你仍然有脂肪分解和血糖调节的控制，</span>”<span style="font-size: 18px; font-family: 宋体;">上述论文的第一作者、罗纳德·埃文斯实验室的博士后研究员简恩瑟·桑贾尔（</span>Gencer Sancar<span style="font-size: 18px; font-family: 宋体;">）说。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">寻找</span>PDE4<span style="font-size: 18px; font-family: 宋体;">通路为专注于高血糖（</span>hyperglycemia<span style="font-size: 18px; font-family: 宋体;">）和胰岛素抵抗的药物发现和基础研究开辟了新的机会。科学家们渴望研究修饰</span>FGF1<span style="font-size: 18px; font-family: 宋体;">以提高</span> PDE4 <span style="font-size: 18px; font-family: 宋体;">活性的可能性。另一种途径是在激活</span>PDE4<span style="font-size: 18px; font-family: 宋体;">之前针对信号通路中的多个点。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">埃文斯实验室的资深科学家、上述论文的共同通讯作者迈克尔·唐斯（</span>Michael Downes<span style="font-size: 18px; font-family: 宋体;">）说：</span>“FGF1<span style="font-size: 18px; font-family: 宋体;">在胰岛素抵抗糖尿病小鼠中诱导持续降低血糖的独特能力，是糖尿病患者的一条有前途的治疗途径。我们希望深入了解这一途径，将为糖尿病患者带来更好的治疗。现在我们有了一条新途径，我们可以弄清楚它在体内能量稳态中的作用以及如何对其进行操纵。</span>”</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><span style="font-size: 18px; font-family: 宋体;">此项研究得到了美国国立卫生研究院（</span>National Institutes of Health,<span style="font-size: 18px; font-family: 宋体;">）、诺米斯基金会（</span>Nomis Foundation<span style="font-size: 18px; font-family: 宋体;">）、</span>March of Dimes<span style="font-size: 18px; font-family: 宋体;">、德国科学研究基金会</span>(Deutsche Forschungsgemeinschaft<span style="font-size: 18px; font-family: 宋体;">简称</span>DFG)<span style="font-size: 18px; font-family: 宋体;">、荷兰科学研究组织（</span>Netherlands Organization for Scientific Research<span style="font-size: 18px; font-family: 宋体;">）、欧洲糖尿病研究基金会（</span>European Foundation for the Study of Diabetes<span style="font-size: 18px; font-family: 宋体;">）以及瑞士国家科学基金会（</span>Swiss National Science Foundation<span style="font-size: 18px; font-family: 宋体;">）的支持。</span></span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">上述介绍，仅供参考。欲了解更多信息，敬请注意浏览</span><a href="http://dx.doi.org/10.1016/j.cmet.2021.12.004" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">原文</span></a><span style="font-size: 18px; font-family: "times new roman";">或者</span><a href="http://www.sciencedaily.com/releases/2022/01/220104112231.htm" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">相关报道</span></a><span style="font-size: 18px; font-family: "times new roman";">。</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"></span></p><p style="line-height: 2em;"><a href="https://doi.org/10.1016/j.cmet.2021.12.004" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><strong><span style="font-size: 18px; font-family: "times new roman";">Highlights</span></strong></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• FGF1-FGFR1 signaling suppresses adipose lipolysis to curb hepatic glucose production</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• FGF1 suppresses lipolysis by inhibiting cAMP/PKA axis via PDE4D-S44 phosphorylation</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• Overexpression of PDE4D in the adipose tissue of diabetic mice corrects hyperglycemia</span></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">• FGF1/PDE4D antilipolytic pathway is responsive to fed/fast states</span></p><p style="line-height: 2em;"><a href="https://doi.org/10.1016/j.cmet.2021.12.004" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><strong><span style="font-size: 18px; font-family: "times new roman";">Summary</span></strong></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";">Inexorable increases in insulin resistance, lipolysis, and hepatic glucose production (HGP) are hallmarks of type 2 diabetes. Previously, we showed that peripheral delivery of exogenous fibroblast growth factor 1 (FGF1) has robust anti-diabetic effects mediated by the adipose FGF receptor (FGFR) 1. However, its mechanism of action is not known. Here, we report that FGF1 acutely lowers HGP by suppressing adipose lipolysis. On a molecular level, FGF1 inhibits the cAMP-protein kinase A axis by activating phosphodiesterase 4D (PDE4D), which separates it mechanistically from the inhibitory actions of insulin via PDE3B. We identify Ser44 as an FGF1-induced regulatory phosphorylation site in PDE4D that is modulated by the feed-fast cycle. These findings establish the FGF1/PDE4 pathway as an alternate regulator of the adipose-HGP axis and identify FGF1 as an unrecognized regulator of fatty acid homeostasis.</span></p><p style="line-height: 2em;"><a href="https://doi.org/10.1016/j.cmet.2021.12.004" style="text-decoration: underline; font-size: 18px; font-family: "times new roman";" target="_blank"><span style="font-size: 18px; font-family: "times new roman";">Graphical abstract</span></a></p><p style="line-height: 2em;"><span style="font-size: 18px; font-family: "times new roman";"><img src="https://cors.zfour.workers.dev/?http://image.sciencenet.cn/home/202201/05/214231j9f6jzwgu2ae6n02.jpg" title alt="01 xu yu.jpg" referrerpolicy="no-referrer"><br></span></p><p style="line-height: 2em;"><font face="times new roman"><span style="font-size: 18px;"><br></span></font></p>                    <br><br>
                                        <label style="font-size:13px; color:#850f0f">转载本文请联系原作者获取授权，同时请注明本文来自诸平科学网博客。<br>链接地址：</label><a href="https://blog.sciencenet.cn/blog-212210-1319732.html" target="_blank" style="font-size:13px; color:#850f0f">https://blog.sciencenet.cn/blog-212210-1319732.html </a>
  <br><br>上一篇：<a href="http://blog.sciencenet.cn/blog-212210-1319597.html" target="_black">让“死”锂复活，恢复电池活力</a><br>                    <!--大赛结束-->
                                        
  
</div>
            